Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis. (2024)
https://pubmed.ncbi.nlm.nih.gov/39076975/

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study. (2024)
https://pubmed.ncbi.nlm.nih.gov/39053949/

Psoriatic dactylitis: from immunopathogenesis to anti-cytokine and targeted synthetic therapies (2024)
https://pubmed.ncbi.nlm.nih.gov/39212137/

The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis. (2024)
https://pubmed.ncbi.nlm.nih.gov/39037828/

Psoriatic Arthritis Acceptable Symptoms State: Does Sex Make a Difference? (2024)
https://pubmed.ncbi.nlm.nih.gov/39003339/

Editorial: New insights into spondyloarthritis: from bench to bedside. (2024)
https://pubmed.ncbi.nlm.nih.gov/38860027/

Study of lncRNAs expression profile in the response to biological drugs in Psoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy. (2024)
https://pubmed.ncbi.nlm.nih.gov/38761785/

Impact of HLA-B51 on Uveitis and Retinal Vasculitis: Data from the AIDA International Network Registries on Ocular Inflammatory Disorders. (2024)
https://pubmed.ncbi.nlm.nih.gov/38759215/

The steroid-sparing effect of JAK inhibitors across multiple patient populations. Front Immunol. (2024)
https://pubmed.ncbi.nlm.nih.gov/38680499/

Evaluation of diagnostic and therapeutic delay in patients with rheumatoid arthritis and psoriatic arthritis. (2024)
https://pubmed.ncbi.nlm.nih.gov/38523584/

The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus. (2024)
https://pubmed.ncbi.nlm.nih.gov/38521214/

Pain in axial spondyloarthritis: role of the JAK/STAT pathway (2024)
https://pubmed.ncbi.nlm.nih.gov/38464510/

Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases. (2024)
https://pubmed.ncbi.nlm.nih.gov/38296800/

Sensitivity and Specificity of Composite Indices of Remission in Male and Female Patients With Psoriatic Arthritis: A Multicenter Cross-Sectional Study of Longitudinal Cohorts. (2024)
https://pubmed.ncbi.nlm.nih.gov/38101911/

Osteoimmunology of Spondyloarthritis (2024)
https://pubmed.ncbi.nlm.nih.gov/37834372/

Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs (2023)
https://pubmed.ncbi.nlm.nih.gov/37650298/

Rheumatologist’s Perspective on Non-Infectious Uveitis: Patterns from Tertiary Referral Rheumatologic Clinics in Italy (2023)
https://pubmed.ncbi.nlm.nih.gov/37298638/

Psoriatic Arthritis in Males and Females: Differences and Similarities. (2023)
https://pubmed.ncbi.nlm.nih.gov/36795290/

How Has Molecular Biology Enhanced Our Undertaking of axSpA and Its Management (2023)
https://pubmed.ncbi.nlm.nih.gov/36308677/

Micronutrients deficiencies in patients with spondylarthritis: the potential immunometabolic crosstalk in disease phenotype. (2022)
https://pubmed.ncbi.nlm.nih.gov/35363353/

Multicenter Validation of the DETAIL Questionnaire for the Screening of Spondyloarthritis in Patients With Inflammatory Bowel Diseases. (2021)
https://pubmed.ncbi.nlm.nih.gov/32669448/

ex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients. (2021)
https://pubmed.ncbi.nlm.nih.gov/34876490/

Tackling the autoimmune side in Spondyloarthritis: A systematic review. (2020)
https://pubmed.ncbi.nlm.nih.gov/32801035/

Enteropathic spondyloarthritis: Results from a large nationwide database analysis. (2020)
https://pubmed.ncbi.nlm.nih.gov/31838160/